DONGWHA PHARM.CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,700 KRW | -0.46% |
|
+1.87% | -15.29% |
| Sales 2022 | 340B 247M | Sales 2023 | 361B 263M | Capitalization | 284B 207M |
|---|---|---|---|---|---|
| Net income 2022 | 20.38B 14.82M | Net income 2023 | 27.44B 19.95M | EV / Sales 2022 | 0.46 x |
| Net cash position 2022 | 101B 73.45M | Net cash position 2023 | 41.73B 30.34M | EV / Sales 2023 | 0.67 x |
| P/E ratio 2022 |
12.6
x | P/E ratio 2023 |
10.4
x | Employees | 810 |
| Yield 2022 |
1.94% | Yield 2023 |
1.75% | Free-Float | 61.76% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.46% | ||
| 1 week | +1.87% | ||
| Current month | -7.45% | ||
| 1 month | -9.00% | ||
| 3 months | -11.13% | ||
| 6 months | -9.09% | ||
| Current year | -15.29% |
1 week
8 500.00
8 810.00
1 month
8 340.009 590.00
Current year
8 340.0010 760.00
1 year
8 310.0011 120.00
3 years
8 060.0021 550.00
5 years
4 800.0034 450.00
10 years
4 800.0034 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jun-Ha Yoo
CEO | Chief Executive Officer | 60 | - |
Ma-Se Lee
CTO | Chief Tech/Sci/R&D Officer | 61 | - |
Dae-Hyun Kim
BRD | Director/Board Member | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Do-Joon Yoon
PRN | Corporate Officer/Principal | 72 | - |
In-Ho Yoon
BRD | Director/Board Member | 40 | - |
Sem-An Oh
BRD | Director/Board Member | 68 | 19-03-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 8,700 | -0.46% | 29,465 |
| 24-04-25 | 8,740 | +0.34% | 17,158 |
| 24-04-24 | 8,710 | +0.81% | 18,221 |
| 24-04-23 | 8,640 | -0.69% | 47,912 |
| 24-04-22 | 8,700 | +2.72% | 45,578 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.29% | 176M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B |
- Stock Market
- Equities
- A000020 Stock
